ID: ALA2088198

Max Phase: Preclinical

Molecular Formula: C24H28N2O2

Molecular Weight: 376.50

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCc1cc2c(cc1CC)CC(NCCc1ccc(O)c3[nH]c(=O)ccc13)C2

Standard InChI:  InChI=1S/C24H28N2O2/c1-3-15-11-18-13-20(14-19(18)12-16(15)4-2)25-10-9-17-5-7-22(27)24-21(17)6-8-23(28)26-24/h5-8,11-12,20,25,27H,3-4,9-10,13-14H2,1-2H3,(H,26,28)

Standard InChI Key:  ZQWNZUAMWNPQGR-UHFFFAOYSA-N

Associated Targets(Human)

Beta-2 adrenergic receptor 11824 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Beta-1 adrenergic receptor 6630 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Dopamine D2 receptor 23596 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Beta-2 adrenergic receptor 1382 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 376.50Molecular Weight (Monoisotopic): 376.2151AlogP: 3.66#Rotatable Bonds: 6
Polar Surface Area: 65.12Molecular Species: BASEHBA: 3HBD: 3
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 8.85CX Basic pKa: 10.33CX LogP: 4.04CX LogD: 2.81
Aromatic Rings: 3Heavy Atoms: 28QED Weighted: 0.62Np Likeness Score: 0.22

References

1. Beattie D, Beer D, Bradley ME, Bruce I, Charlton SJ, Cuenoud BM, Fairhurst RA, Farr D, Fozard JR, Janus D, Rosethorne EM, Sandham DA, Sykes DA, Trifilieff A, Turner KL, Wissler E..  (2012)  An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol.,  22  (19): [PMID:22932315] [10.1016/j.bmcl.2012.07.096]

Source